Overexpression of TIM-3 on exhausted CD4+ and CD8+ T cells and leukemic cells in CML, ALL, and CLL patients could be a prognostic risk factor for poor therapeutic response and relapse in patients. The gene discussed is HAVCR2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.